SCHEMBL3958675

SCHEMBL3958675

COC(=O)c1[nH]nnc1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 1/20 0.43
MAPK1 P28482 1/20 0.39
MAPT P10636 3/20 0.38
NPSR1 Q6W5P4 1/20 0.37
ALPL P05186 6/20 0.36
TSHR P16473 1/20 0.34
ALDH1A1 P00352 2/20 0.34
HSD17B10 Q99714 2/20 0.34
GAA P10253 1/20 0.33
RAB9A P51151 2/20 0.33
POLB P06746 1/20 0.33
KMT2A Q03164 2/20 0.32
MEN1 O00255 1/20 0.32
HPGD P15428 1/20 0.32
F2 P00734 1/20 0.32
NPC1 O15118 1/20 0.32
LMNA P02545 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
KDM4E B2RXH2 1/20 0.32
STAT3 P40763 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31332908 0.79 CYP1A2 (0.44) ALPLALDH1A1HSD17B10POLBKMT2A
SCHEMBL1930167 0.78 KDM4C (0.53) KDM4CMAPK1MAPTNPSR1ALPL
SCHEMBL9587880 0.78 KDM4C (0.44) KDM4CMAPK1MAPTNPSR1ALPL
SCHEMBL9642740 0.76 KDM4C (0.43) KDM4CMAPK1MAPTNPSR1ALPL
SCHEMBL21621367 0.76 PDK2 (0.42) MAPTKMT2ANPC1SMN1; SMN2KDM4E
SCHEMBL23294432 0.76 KDM4C (0.43) KDM4CMAPK1MAPTNPSR1ALPL
SCHEMBL2385273 0.74 KDM4C (0.46) KDM4CMAPK1NPSR1TSHRALDH1A1
SCHEMBL23939800 0.74
SCHEMBL7425496 0.73 KDM4C (0.41) KDM4CMAPK1MAPTNPSR1ALPL
SCHEMBL19661284 0.71 KDM4C (0.46) KDM4CMAPK1MAPTNPSR1ALPL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260078130-A1 NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF SIRONAX LTD (KY) 2026-03-19 US disclosed
EP-4590674-A1 NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF Sironax Ltd (KY) 2025-07-30 EP disclosed
US-11008416-B2 Aqueous, curable composition, comprising dispersed uretdione prepolymer, reactant and azolate COVESTRO LLC (US) 2021-05-18 US disclosed
US-20210017322-A1 URETDIONE-CONTAINING POLYURETHANE-DISPERSIONS COMPRISING HYDROPHILIC GROUPS COVESTRO DEUTSCHLAND AG (DE) 2021-01-21 US disclosed
CN-111886271-A Aqueous curable compositions comprising dispersed uretdione prepolymers, reactants, and azoles 科思创有限公司 2020-11-03 CN disclosed
CN-111868131-A Uretdione-containing polyurethane dispersions containing hydrophilic groups 科思创德国股份有限公司 2020-10-30 CN disclosed
US-20190292299-A1 AQUEOUS, CURABLE COMPOSITION, COMPRISING DISPERSED URETDIONE PREPOLYMER, REACTANT AND AZOLATE COVESTRO LLC 2019-09-26 US disclosed
EP-3543269-A1 URETDIONE-CONTAINING POLYURETHANE-DISPERSIONS COMPRISING HYDROPHILIC GROUPS Covestro Deutschland AG (DE) 2019-09-25 EP disclosed
EP-1937682-B1 MET KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2015-08-12 EP disclosed
EP-1389221-B1 METHOD FOR PRODUCING ALIPHATIC POLYISOCYANATES HAVING AN URETDIONE, ISOCYANURATE AND IMINOOXADIAZINDIONE STRUCTURE BAYER MATERIALSCIENCE AG (DE) 2009-07-22 EP disclosed
US-20070078140-A1 MET kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2007-04-05 US disclosed
US-20070078140-A1 MET kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2007-04-05 US disclosed
US-7030266-B2 Method for producing polyisocyanates BAYER AKTIENGESELLSCHAFT (DE) 2006-04-18 US disclosed
EP-1389221-A1 METHOD FOR PRODUCING ALIPHATIC POLYISOCYANATES HAVING AN URETDIONE, ISOCYANURATE AND IMINOOXADIAZINDIONE STRUCTURE Bayer Aktiengesellschaft (DE) 2004-02-18 EP disclosed
EP-1389223-A1 METHOD FOR PRODUCING POLYISOCYANATES Bayer Aktiengesellschaft (DE) 2004-02-18 EP disclosed
US-6590098-B2 Reacting isocyanates-2+ such as hexamethylene diisocyanate in the presence of catalysts, to form dimers, trimers and/or adducts used as polyurethane paints and coatings BAYER AKTIENGESELLSCHAFT (DE) 2003-07-08 US disclosed
US-20030078361-A1 Method of preparing aliphatic polyisocyanates with uretdione, isocyanurate and iminooxadiazindione structures BAYER AKTIENGESELLSCHAFT (DE) 2003-04-24 US disclosed
US-20030078450-A1 Method for producing polyisocyanates COVESTRO DEUTSCHLAND AG (DE) 2003-04-24 US disclosed
WO-2002092658-A1 METHOD FOR PRODUCING POLYISOCYANATES BAYER AKTIENGESELLSCHAFT (DE) 2002-11-21 WO disclosed
WO-2002092656-A1 METHOD FOR PRODUCING ALIPHATIC POLYISOCYANATES HAVING AN URETDIONE, ISOCYANURATE AND IMINOOXADIAZINDIONE STRUCTURE BAYER AKTIENGESELLSCHAFT (DE) 2002-11-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260078130-A1 NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF NAMPT, NNMT, SARM1 KDM4C 3237/4885MAPK1 1908/4885MAPT 523/4885
US-20030078450-A1 Method for producing polyisocyanates HDHD5, NISCH, DOHH KDM4C 704/4885MAPK1 3560/4885MAPT 3422/4885
US-20070078140-A1 MET kinase inhibitors MET, ABL1, ERBB2 KDM4C 1016/4885MAPK1 227/4885MAPT 3276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.